Aminoglutethimide 250mg tablets
An aromatase inhibitor that produces a state of "medical" adrenalectomy by blocking the production of adrenal steroids.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Aminoglutethimide
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Aminoglutethimide
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
WHO defined daily dose (DDD)
1 gram
Not a recommended dose. The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. It is a statistical measure used for research and comparison purposes only.
Source: WHO Collaborating Centre for Drug Statistics Methodology, distributed via the NHS dm+d supplementary BNF/ATC mapping files (NHSBSA). Contains public sector information licensed under the Open Government Licence v3.0.
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 10 · Randomised trials: 13 · 1967–2025
Showing the 50 most relevant studies, sorted by most relevant.
M. Gershanovich, H. Chaudri, D. Campos, et al.
Annals of oncology : official journal of the European Society for Medical Oncology, 1998
- Letrozole
- Aminoglutethimide
- Breast Neoplasms
Richard J. Santen, Thomas J. Worgul, E Samojlik, et al.
New England Journal of Medicine, 1981
- Adrenalectomy
- Aminoglutethimide
- Breast Neoplasms
Ian E. Smith, Adrian L. Harris, Myfanwy Morgan, et al.
BMJ, 1981
- Aminoglutethimide
- Bone Neoplasms
- Breast Neoplasms
Allan Lipton, Harold A. Harvey, Richard J. Santen, et al.
Cancer, 1982
- Aminoglutethimide
- Breast Neoplasms
- Castration
R. Santen, S. Santner, B. Davis, et al.
The Journal of clinical endocrinology and metabolism, 1978
- Menopause
- Aminoglutethimide
- Androstenedione
R. N. Dexter, Lawrence M. Fishman, Robert L. Ney, et al.
The Journal of Clinical Endocrinology & Metabolism, 1967
- Adrenal Cortex Hormones
- Adrenal Glands
- Adrenocorticotropic Hormone
Ralph Cash, A. Joseph Brough, MARGO N. P. COHEN, et al.
The Journal of Clinical Endocrinology & Metabolism, 1967
- Adrenal Cortex Hormones
- Adrenal Glands
- Adrenocorticotropic Hormone
M. Schmid, R. Jakesz, H. Samonigg, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2003
- Aminoglutethimide
- Antineoplastic Combined Chemotherapy Protocols
- Austria
J. Ingle, Green Sj, D. Ahmann, et al.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1986
- Aminoglutethimide
- Antineoplastic Combined Chemotherapy Protocols
- Breast Neoplasms
Richard J. Santen, Robert I. Misbin
Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy, 1981
- ACTH Syndrome, Ectopic
- Adrenal Cortex
- Adrenal Gland Neoplasms
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
1.6 hours
Mechanism
Aminoglutethimide reduces the production of D5-pregnenolone and blocks several o…
Food interactions
1 warning
Human targets
2 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
Half-life
1.6 hours
Protein binding
21-25%
Metabolism
34-54%
Elimination
34%
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 346 interactions
How the body processes this drug — absorption, distribution, metabolism, and elimination
Proteins and enzymes this drug interacts with in the body
PMID:21636783
Catalyzes three sequential oxidation reactions of cholesterol, namely the hydroxylation at C22 followed with the hydroxylation at C20 to yield 20R,22R-hydroxycholesterol that is further cleaved between C20 and C22 to yield the C21-steroid pregnenolone and 4-methylpentanal .
PMID:21636783
Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate and reducing the second into a water molecule. Two electrons are provided by NADPH via a two-protein mitochondrial transfer system comprising flavoprotein FDXR (adrenodoxin/ferredoxin reductase) and nonheme iron-sulfur protein FDX1 or FDX2 (adrenodoxin/ferredoxin) PMID:21636783
PMID:27702664 PMID:2848247
Catalyzes three successive oxidations of C19 androgens: two conventional oxidations at C19 yielding 19-hydroxy and 19-oxo/19-aldehyde derivatives, followed by a third oxidative aromatization step that involves C1-beta hydrogen abstraction combined with cleavage of the C10-C19 bond to yield a phenolic A ring and formic acid .
PMID:20385561
Alternatively, the third oxidative reaction yields a 19-norsteroid and formic acid. Converts dihydrotestosterone to delta1,10-dehydro 19-nordihydrotestosterone and may play a role in homeostasis of this potent androgen .
PMID:22773874
Also displays 2-hydroxylase activity toward estrone .
PMID:22773874
Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (CPR; NADPH-ferrihemoprotein reductase) PMID:20385561 PMID:22773874
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L02BG01
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Aminoglutethimide
Additional database identifiers
Drugs Product Database (DPD)
1927
ChemSpider
2060
BindingDB
9460
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2590
GeneCards
CYP11A1
GenBank Gene Database
M14565
GenBank Protein Database
181376
Guide to Pharmacology
1358
UniProt Accession
CP11A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2594
GenAtlas
CYP19A1
GeneCards
CYP19A1
GenBank Gene Database
M22246
GenBank Protein Database
179002
Guide to Pharmacology
1362
UniProt Accession
CP19A_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2621
GeneCards
CYP2C19
GenBank Gene Database
M61854
GenBank Protein Database
181344
Guide to Pharmacology
1328
UniProt Accession
CP2CJ_HUMAN
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q241150), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication. WHO INN from the World Health Organization.